[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Cytomx Thera (CTMX)

Cytomx Thera (CTMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 699,456
  • Shares Outstanding, K 217,899
  • Annual Sales, $ 76,200 K
  • Annual Income, $ -17,370 K
  • EBIT $ -87 M
  • EBITDA $ -88 M
  • 60-Month Beta 2.12
  • Price/Sales 9.78
  • Price/Cash Flow N/A
  • Price/Book 1.93

Options Overview Details

View History
  • Implied Volatility 104.43% (+20.32%)
  • Historical Volatility 49.04%
  • IV Percentile 41%
  • IV Rank 17.25%
  • IV High 329.23% on 03/10/26
  • IV Low 57.55% on 05/08/26
  • Expected Move (DTE 19) 0.33 (10.33%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 83
  • Volume Avg (30-Day) 631
  • Put/Call OI Ratio 0.61
  • Today's Open Interest 14,577
  • Open Int (30-Day) 24,581
  • Expected Range 2.88 to 3.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.09
  • Number of Estimates 3
  • High Estimate $-0.08
  • Low Estimate $-0.11
  • Prior Year $-0.09
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.01 +6.64%
on 08/03/26
3.60 -10.83%
on 08/19/26
-0.01 (-0.31%)
since 07/28/26
3-Month
2.82 +14.03%
on 06/09/26
4.02 -20.15%
on 07/10/26
-0.50 (-13.48%)
since 05/28/26
52-Week
1.90 +68.95%
on 09/16/25
8.21 -60.90%
on 03/16/26
+1.16 (+56.59%)
since 08/28/25

Most Recent Stories

More News
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)

- Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC - - Potential Varseta-M monotherapy registrational study in R/R mCRC planned for initiation in...

CTMX : 3.21 (-6.14%)
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)

- Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC -

CTMX : 3.21 (-6.14%)
CytomX Therapeutics: Q2 Earnings Snapshot

CytomX Therapeutics: Q2 Earnings Snapshot

CTMX : 3.21 (-6.14%)
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

Varsetatug masetecan (“Varseta-M”) Program: - Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational...

CTMX : 3.21 (-6.14%)
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

Varsetatug masetecan (“Varseta-M”) Program: - Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027...

CTMX : 3.21 (-6.14%)
CytomX Reports Tomorrow With Analysts Already Looking Past August

Barchart Research What to Expect from CTMX Earnings CTMX Generated August 5, 2026 Current Price $3.35 EPS Estimate $$-0.11 Consensus Rating Strong Buy Average Move 25.62% CytomX Reports Tomorrow With Analysts...

CTMX : 3.21 (-6.14%)
CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment...

CTMX : 3.21 (-6.14%)
CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026

SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will...

CTMX : 3.21 (-6.14%)
CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026

SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally...

CTMX : 3.21 (-6.14%)
CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors

SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally...

CTMX : 3.21 (-6.14%)

Business Summary

CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 3.56
2nd Resistance Point 3.49
1st Resistance Point 3.35
Last Price 3.21
1st Support Level 3.14
2nd Support Level 3.07
3rd Support Level 2.93

See More

52-Week High 8.21
Fibonacci 61.8% 5.80
Fibonacci 50% 5.05
Fibonacci 38.2% 4.31
Last Price 3.21
52-Week Low 1.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.